List view / Grid view
Genzyme will have significant rights to Alnylam’s portfolio of clinical…
13 January 2014 | By Sanofi
Genzyme will have significant rights to Alnylam’s portfolio of clinical and pre-clinical stage drug candidates...
Data presented at ECTRIMS highlight potential of early intervention with…
3 October 2013 | By Sanofi
Data presented at ECTRIMS highlight potential of early intervention with Aubagio to delay second clinical attack and reduce MRI lesion burden...
Sanofi and its subsidiary Genzyme announced that the European Commission…
30 August 2013 | By Sanofi
Sanofi and its subsidiary Genzyme announced that the European Commission has granted marketing authorization for Aubagio® (teriflunomide)...
Sanofi announced the appointment of two new members to the…
31 July 2013 | By Sanofi
Sanofi announced the appointment of two new members to the Executive Committee, effective September 1st, 2013...
"Today’s CHMP opinions set the stage for the approval of…
28 June 2013 | By Sanofi
"Today’s CHMP opinions set the stage for the approval of two important new treatment options..."
Genzyme announced positive top-line results from the TOPIC trial for…
25 April 2013 | By Sanofi
Genzyme announced positive top-line results from the TOPIC trial for AUBAGIO...
Results from the first year of the extension study of…
21 March 2013 | By Sanofi
Results from the first year of the extension study of LEMTRADA™ (alemtuzumab)...
“Today’s FDA approval of KYNAMRO is great news..."
29 January 2013 | By Sanofi
“Today’s FDA approval of KYNAMRO is great news..."
Genzyme also reports very encouraging early launch indicators for AUBAGIO®…
28 January 2013 | By Sanofi
Genzyme also reports very encouraging early launch indicators for AUBAGIO® (teriflunomide) in U.S.
"We are disappointed by the Committee's recommendation..."
14 December 2012 | By Sanofi
"We are disappointed by the Committee's recommendation..."
Significant effects of LEMTRADA™ vs. Rebif ® described in CARE-MS…
31 October 2012 | By
Significant effects of LEMTRADA™ vs. Rebif ® described in CARE-MS I and CARE-MS II publications...
"We are very encouraged by the support for KYNAMRO..."
18 October 2012 | By Sanofi
"We are very encouraged by the support for KYNAMRO..."
Sanofi and Genzyme announced that key data from the TOWER…
12 October 2012 | By Sanofi
Sanofi and Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the ECTRIMS...
New data from Genzyme’s clinical development programs...
9 October 2012 | By Genzyme
New data from Genzyme’s clinical development programs...
AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing Multiple Sclerosis...
12 September 2012 | By Sanofi
AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing Multiple Sclerosis...
